Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Centocor, Inc. Clear all
Completed Phase 3 Interventional Results available

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

NCT00046228
View directory record Official record
Conditions
Myocardial Infarction
Interventions
abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
21 Years and older
Enrollment
2,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
52
States / cities
Phoenix, Arizona • Covina, California • Modesto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

NCT00402181
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Dexamethasone
Biological · Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

NCT00796809
View directory record Official record
Conditions
Coccidioidomycosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

NCT01144143
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Infliximab, Placebo, Standard of Care: Methylprednisolone acetate
Drug
Lead sponsor
Herbert Lindsley, MD
Other
Eligibility
35 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 7, 2026, 10:41 AM EDT
Withdrawn Not applicable Interventional

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NCT01266785
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 7, 2026, 10:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Beryllium Infliximab Study: Clinical Interventional Trial

NCT00111917
View directory record Official record
Conditions
Berylliosis, Beryllium Disease
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Maier, Lisa, M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

NCT00888043
View directory record Official record
Conditions
Solid Tumors
Interventions
CNTO 95 and avastin
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

NCT00207740
View directory record Official record
Conditions
Asthma
Interventions
CNTO148, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • Stockton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

NCT00412321
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
Interventions
CNTO 328
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Little Rock, Arkansas • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

NCT00771667
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Centocor Microarray Study of Patients

NCT00462072
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

NCT00973479
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab, Placebo, methotrexate (MTX)
Drug · Other
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636
View directory record Official record
Conditions
Crohn's Disease
Interventions
infliximab, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

NCT00264537
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

NCT01362153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

NCT00955279
View directory record Official record
Conditions
Sarcoidosis
Interventions
Placebo, Golimumab, Ustekinumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed No phase listed Observational

Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry

NCT00833170
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
1 Month to 16 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Hartford, Connecticut • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 7, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

NCT00458575
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
CNTO 2476
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Miami, Florida • Southwest Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

NCT01258777
View directory record Official record
Conditions
Healthy Volunteers
Interventions
400 mg golimumab or placebo, 200 mg golimumab or placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
strength training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 7, 2026, 10:41 AM EDT